Kwality Pharmaceuticals Limited
BSE: KPL · Pharmaceuticals
Snapshot
Unlock Kwality Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kwality Pharmaceuticals Ltd. is an Indian pharmaceutical company specialising in the manufacture of diverse dosage forms, including tablets, injectables, and liquid orals. The company operates primarily as a manufacturer of pharmaceutical formulations.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical formulations across various therapeutic categories. It serves both domestic and international markets by leveraging its manufacturing capabilities in multiple dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its product portfolio and the increasing demand for affordable pharmaceutical formulations. The company continues to focus on enhancing its manufacturing capacity to cater to broader market requirements.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by global health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) can adversely impact profit margins.
- Intense Market Competition. The pharmaceutical formulation sector is highly competitive, which may exert pressure on product pricing and market share.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect its international revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Kwality Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹554 Cr
TTM · consolidated
NET PROFIT
₹81 Cr
TTM · consolidated
EPS
₹78.10
TTM · consolidated
RETURN ON EQUITY
27.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
36.4%
TTM · consolidated
P/E
45.6×
Q1 FY27 · consolidated
EV/EBITDA
28.9x
Q1 FY27 · consolidated
EBITDA MARGIN
24.9%
TTM · consolidated
NET PROFIT MARGIN
15.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Kwality Pharmaceuticals LimitedKPL | ₹3,865 Cr | 45.6× | 28.91 | 37.9% | 24.9% | 27.2% | 36.4% | +294.1% |
Gufic Biosciences LimitedGUFICBIO | ₹4,387 Cr | 57.2× | 28.23 | 16.7% | 17.0% | 11.6% | 16.9% | +19.2% |
Unichem Laboratories LimitedUNICHEMLAB | ₹4,036 Cr | 12.2× | 14.03 | 9.4% | 13.0% | 11.8% | 14.1% | +10.9% |
Aarti Drugs LimitedAARTIDRUGS | ₹3,982 Cr | 20.1× | 13.53 | — | 12.6% | 13.1% | 14.5% | -13.7% |
Ind-Swift Laboratories LimitedINDSWFTLAB | ₹3,517 Cr | 57.9× | 27.01 | 113.3% | 17.3% | 4.5% | 5.5% | +305.8% |
Solara Active Pharma Sciences LimitedSOLARA | ₹3,449 Cr | -1153.0× | 20.59 | 15.5% | 13.9% | -0.1% | 6.7% | +18.1% |
As of Q1 FY27
Financials
Kwality Pharmaceuticals Limited
BSE: KPL · Pharmaceuticals
Snapshot
Unlock Kwality Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kwality Pharmaceuticals Ltd. is an Indian pharmaceutical company specialising in the manufacture of diverse dosage forms, including tablets, injectables, and liquid orals. The company operates primarily as a manufacturer of pharmaceutical formulations.
Business Model
The company generates revenue through the large-scale production and sale of pharmaceutical formulations across various therapeutic categories. It serves both domestic and international markets by leveraging its manufacturing capabilities in multiple dosage forms.
Growth Outlook
Growth is expected to be driven by the expansion of its product portfolio and the increasing demand for affordable pharmaceutical formulations. The company continues to focus on enhancing its manufacturing capacity to cater to broader market requirements.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by global health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) can adversely impact profit margins.
- Intense Market Competition. The pharmaceutical formulation sector is highly competitive, which may exert pressure on product pricing and market share.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect its international revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Kwality Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹554 Cr
TTM · consolidated
NET PROFIT
₹81 Cr
TTM · consolidated
EPS
₹78.10
TTM · consolidated
RETURN ON EQUITY
27.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
36.4%
TTM · consolidated
P/E
45.6x
Q1 FY27 · consolidated
EV/EBITDA
28.9x
Q1 FY27 · consolidated
EBITDA MARGIN
24.9%
TTM · consolidated
NET PROFIT MARGIN
15.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.4x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27